Soft Tissue Sarcomas: Emerging and Novel Concepts
Soft tissue sarcomas are a rare and challenging group of malignancies of mesenchymal origin that have historically been treated with similar approaches.
Mutant-Specific Epidermal Growth Factor Receptor Inhibitors
Treating sensitizing EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) leads to better outcomes compared with standard chemotherapy.
Immune Checkpoint Inhibitors for Renal Cell Carcinoma
It is estimated that 1 in 63 individuals in the United States will develop renal cell carcinoma (RCC), making it among the most common cancers in the country.
